CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of the Urological Oncology Rehabilitation Committee of the Chinese Anti-Cancer Association and Director of General Surgery and Urology at United Family Healthcare, presented insights on individualized treatment for prostate cancer. Urology Frontier had the opportunity to delve deeper into this topic with Professor Zhu.
An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer

An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer

On November 23rd, Dr. Tianshu Liu's team from Zhongshan Hospital published a study titled "Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial" in JNCI Cancer Spectrum(IF=3.4). The PRESERVE 1 trial sheds light on trilaciclib's potential to reduce chemotherapy-related toxicity in mCRC. While its efficacy in mitigating myelosuppression is evident, the antitumor results are concerning. Further studies are needed to explore the balance between toxicity reduction and efficacy, and to determine trilaciclib's optimal use in cancer treatment.

AASLD 2024丨Dr. Jinlin Hou’s Team: Cost-Effectiveness of aMAP Score-Guided Individualized HCC Screening in HBsAg-Positive Populations

Hepatocellular carcinoma (HCC) imposes a significant health and economic burden on patients. Screening, recognized as an effective strategy to improve early diagnosis rates in high-risk populations, has garnered broad acknowledgment in the field. Current HCC screening techniques primarily rely on abdominal ultrasound (US) and alpha-fetoprotein (AFP) testing. However, these methods have limitations: the accuracy of ultrasound can be affected by subcutaneous fat thickness, and AFP has a relatively low detection rate for early-stage HCC.
CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.
CCHIO 2024 | Dr. Huaqing Wang: Exploring Bispecific Antibodies in Lung Cancer

CCHIO 2024 | Dr. Huaqing Wang: Exploring Bispecific Antibodies in Lung Cancer

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has rapidly advanced in the treatment of lung cancer in recent years. However, challenges remain, such as limited efficacy with monotherapy and increased side effects with combination therapies. Multi-targeted combination therapies represent a potential avenue for advancing immunotherapy. Among them, bispecific antibodies (BsAbs), which simultaneously target two different antigens or epitopes, have emerged as a focus of attention for their ability to enhance the immune system's recognition and destruction of tumor cells.
Dr. Ting Deng: ADC Combination Strategies for Gastric Cancer – Directions and Advances | CSCO Gastric Cancer Committee Annual Meeting

Dr. Ting Deng: ADC Combination Strategies for Gastric Cancer – Directions and Advances | CSCO Gastric Cancer Committee Annual Meeting

From November 22 to 24, 2024, the CSCO Gastric Cancer Committee Annual Meeting convened in Beijing, gathering leading experts to discuss the latest advancements, challenges, and opportunities in gastric cancer management. Dr. Ting Deng from Tianjin Medical University Cancer Institute and Hospital delivered a keynote presentation titled "ADC Combination Strategies for Gastric Cancer: Directions and Advances."
CCHIO 2024 | Dr. Xiuyi Zhi: Systematizing Popular Science Efforts to Enhance Public Knowledge, Trust, and Action in Cancer Prevention and Control

CCHIO 2024 | Dr. Xiuyi Zhi: Systematizing Popular Science Efforts to Enhance Public Knowledge, Trust, and Action in Cancer Prevention and Control

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded on November 17, emphasizing a multidisciplinary approach to oncology. The event featured specialized sessions on integrated rehabilitation, public education, and cancer prevention, showcasing novel perspectives and techniques for comprehensive cancer care. During the conference, Oncology Frontier had the honor of interviewing Dr. Xiuyi Zhi, Chief Expert of Thoracic Surgery at Xuanwu Hospital, Capital Medical University, and Director of the Public Education Department of the Chinese Anti-Cancer Association (CACA). Professor Zhi shared the progress in cancer education initiatives and the development of cancer prevention awareness in China.

CCHIO 2024丨Dr. Xiufeng Liu: Exploring the Clinical Potential of the “Cola Combination” from LEAP-002 to LEAP-012

The era of immunotherapy has brought new hope to advanced hepatocellular carcinoma (HCC), with various targeted-immune combination therapies emerging as potential breakthroughs. However, the journey of the "Cola Combination"—pembrolizumab combined with lenvatinib—has been marked by mixed results. In the LEAP-002 trial, the combination showed negative results in the general population but positive outcomes in the Asian subgroup. The LEAP-012 trial further demonstrated the combination's efficacy when paired with transarterial chemoembolization (TACE) in intermediate-stage HCC. Yet, its precise role in clinical practice remains under discussion.
CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis

CTI 2024 | Dr. Ibrahim Yakoub-Agha Discusses the Application of Cellular Immunotherapy in Myelofibrosis

From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the fields of cell therapy and immune therapy from around the world. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Ibrahim Yakoub-Agha from the Lille University , France, to reveal the unlimited potential and broad prospects of cellular immunotherapy in myelofibrosis.